IP Library › Granted Patent US 11,679,099
Granted Patent B2
US 11,679,099 · App. 15/930,799 · Granted Jun 20, 2023

Use of HIF-2α inhibitors for treating chondrosarcoma, or preventing recurrence and metastasis thereof

Inventors: Jin-Hong Kim (Seoul, KR); Hyeonkyeong Kim (Seoul, KR); Hyeon-Seop Kim (Seoul, KR); Yongsik Cho (Seoul, KR)
Assignee: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
A61K31/4245A61K31/277A61K31/704A61K33/243A61P35/04C12N15/1136
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,679,099
App. No.
15/930,799
Granted
Jun 20, 2023
Kind
B2
Abstract

The present disclosure relates a method of treating chondrosarcoma or suppressing metastasis or recurrence thereof by regulating HIF-2α. The present method can be effectively used for treating chondrosarcoma or suppressing metastasis or recurrence thereof by inhibiting HIF-2α during the development and metastasis of chondrosarcoma, particularly dedifferentiated chondrosarcoma.

Claims (4)

1. A method of treating chondrosarcoma or suppressing metastasis or recurrence thereof in a subject in need thereof, the method comprising administering to the subject an effective amount of TC-S7009 [N-(3-Chloro-5-fluorophenyl)-4-nitro-2,1,3-benzoxadiazol-5-amine] and cisplatin,

wherein the subject is a human; and

the TC-S7009 inhibits transcriptional activity of HIF-2α.

2. The method of claim 1 , wherein the chondrosarcoma is a dedifferentiated chondrosarcoma.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 13, 2020
From: KIM, JIN-HONG; KIM, HYEONKYEONG; KIM, HYEON-SEOP; CHO, YONGSIK
To: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
Reel/Frame 052649/0831 →
Continuity (1)
Related Publication 20210353599A1 · Nov 18, 2021